Degree of @entity299 and hypertrophy at time of implantation predicts XXXX during left ventricular assist device support.

@entity1 @entity82 @entity296 @entity712 @entity299
BACKGROUND: There have been increasing reports of cardiac improvement in @entity712 @entity1 supported by left ventricular assist devices (LVADs i.e.), including a number of @entity1 who have tolerated removal of the device without the benefit of cardiac transplant. In the current study, we retrospectively investigated echocardiographic and histologic changes in @entity1 supported by LVADs (n = 18). The goal of our study was to determine if the degree of @entity299 and myocyte size in pre-implant biopsies could predict @entity296 as assessed by improvements in ejection fraction (EF) during LVAD support. METHODS: We determined total collagen content in myocardial biopsy specimens by a semi-quantitative analysis of positive Picro-Sirius Red-stained areas and myocyte size measurements by computerized edge detection software. RESULTS: During LVAD support, 9 of the 18 @entity1 (Group A) were distinguished by significant improvement in ejection fraction (pre <20% vs unloaded 34 +/- 5%). In addition, Group A @entity1 had significantly less @entity82 and smaller myocytes than their Group B counterparts, whose EF did not improve. There was an inverse correlation between pre-implant biopsy collagen levels and myocyte size with increases in EF during LVAD unloading. CONCLUSIONS: We found that the @entity1 who demonstrated the greatest improvements in EF during support had less @entity82 and smaller myocytes at the time of device implantation. We propose that tissue profiling a @entity1 's pre-implant biopsy for @entity82 and myocyte size may allow stratification in Stage IV @entity712 and may predict @entity296 during LVAD support.
